Fracture risk and bone mineral density reduction associated with proton pump inhibitors

Pharmacotherapy

Volumn 32, Issue 1, 2012, Pages 67-79

  Lau, Yuen Ting ^a   Ahmed, Nasiya N ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bone mineral density; Drug toxicity; Fractures; Omeprazole; Osteoporosis; Proton pump inhibitor

Indexed keywords

ALENDRONIC ACID; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BONE DEMINERALIZATION; BONE DENSITY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG WITHDRAWAL; FOREARM FRACTURE; FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SPINE FRACTURE; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; WRIST FRACTURE;

BONE DENSITY; FRACTURES, BONE; HUMANS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84860758216     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1007     Document Type: Review

References (40)

1. Shin JM, Sachs G. Gastric H,KATPase as a drug target. Dig Dis Sci 2006;51:823-33.
2. Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol 2008;103:2428-31.
3. U.S. Food and Drug Administration. Possible fracture risk with high dose, long-term use of proton pump inhibitors. Available from http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm213377.htm. Acessed March 15, 2011.
4. Kirkpantur A, Altun B, Arici M, Turgan C. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clin Pract 2009;63:261-8.
5. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53. (Pubitemid 46021498)
6. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9.
7. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101.
8. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. (Pubitemid 44306164)
9. Chiu H, Huang Y, Chang C, Yang C. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010;19: 1131-6.
10. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 2008;179:319-26.
11. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the women's health initiative. Arch Intern Med 2010;170:765-71.
12. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9.
13. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84:13-9.
14. Yamaguchi T, Sugimoto T, Yamauchi M, Matsumori Y, Tsutsumi M, Chihara K. Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. J Bone Miner Metab 2005;23:36-40.
15. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011;171:998-1004.
16. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2011;22:903-10.
17. de Vries F, Cooper AL, Cockle SM, van Staa T, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009;20:1989-98.
18. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
19. Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2011;9:257-67.
20. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011;48:768-76.
21. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209-18.
22. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary healthcare level. Technical report. Sheffield, United Kingdom: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, 2007.
23. Teramura-Grönblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care 2010;28:154-9.
24. Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HGM. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000;9:359-66.
25. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532-6. (Pubitemid 17123269)
26. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985;313:70-3. (Pubitemid 15068699)
27. Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload: role of gastric acid secretion. Nephron 2002;91:474-9. (Pubitemid 34765248)
28. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-81. (Pubitemid 40897665)
29. Nordin BEC, O'Loughlin PD, Need AG, Horowitz M, Morris HA. Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures. Osteoporos Int 2004;15:27-31. (Pubitemid 38252436)
30. Ensrud KE, Duong T. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium. Ann Intern Med 2000;132:345-53. (Pubitemid 30127772)
31. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int 1998;62:283-5. (Pubitemid 28139307)
32. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010;25:2786-95.
33. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesiumor zinc from foodinhumans.JAmCollNutr1995;14:364- 8.
34. Sarges R, Gallagher A, Chambers TJ, Yeh LA. Inhibition of bone resorption by H+/K+-ATPase inhibitors. J Med Chem 1993;36:2828-30. (Pubitemid 23312680)
35. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K+-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21-5. (Pubitemid 23187327)
36. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H+-ATPase. Curr Pharm Des 2002;8:2033-48. (Pubitemid 34982169)
37. Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar H+-ATPases. Arch Biochem Biophys 2008;476:33-42.
38. Yang YX. Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf 2008;3:204-9.
39. Mattsson JP, Väänänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H + - translocating ATPases. Biochim Biophys Acta 1991;1065:261-8.
40. Samelson EJ, Zhang Y, Kiel DP, Hannan MT, Felson DT. Effect of birth cohort on risk of hip fracture: age-specific incidence rates in the Framingham study. Am J Public Health 2002;92:858-62. (Pubitemid 34441644)